APA (7th ed.) Citation

S, K., S, L., JY, C., SH, Y., IJ, J., & KS, Y. (2017). Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H: Quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials. Dove Medical Press.

Chicago Style (17th ed.) Citation

S, Kim, Lee S, Cho JY, Yoon SH, Jang IJ, and Yu KS. Pharmacokinetics and Tolerability of MB12066, a Beta-lapachone Derivative Targeting NAD(P)H: Quinone Oxidoreductase 1: Two Independent, Double-blind, Placebo-controlled, Combined Single and Multiple Ascending Dose First-in-human Clinical Trials. Dove Medical Press, 2017.

MLA (8th ed.) Citation

S, Kim, et al. Pharmacokinetics and Tolerability of MB12066, a Beta-lapachone Derivative Targeting NAD(P)H: Quinone Oxidoreductase 1: Two Independent, Double-blind, Placebo-controlled, Combined Single and Multiple Ascending Dose First-in-human Clinical Trials. Dove Medical Press, 2017.